Biocon posts 36% growth in Biologics segment in Q1FY19

27 Jul 2018 Evaluate

Biocon has recorded a strong growth of 36% at Rs 250 crore in the Biologics segment in Q1FY19 which comprises of Novel Biologics and Biosimilars. The growth was largely driven by higher sales of biosimilar monoclonal antibodies (mAbs) in emerging markets, supported by Insulins business.

During the quarter, the company’s insulins portfolio gained market share in several emerging markets such as Malaysia, Algeria and UAE. The company’s brand Insugen, now holds a 75% share of the rh-insulin market in Malaysia.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

377.55 -1.50 (-0.40%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×